**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application:

**Listing of Claims:**

1. (Currently amended) A ~~compounds~~ compound of the formula:




or the pharmaceutically acceptable acid salts thereof wherein:

$R_1$ is halogen or $C_1$-$C_4$ alkyl;

$R_2$ and $R_3$ are the same or different and represent hydrogen, halogen, $C_1$-$C_4$ alkyl, $C_1$-$C_4$ alkoxy, alkylthio, hydroxy, amino, monoalkylamino or dialkylamino,

with the proviso that $R_2$ and $R_3$ may not be 2-isopropoxyl and hydrogen respectively when $R_1$ is bromo;

wherein in an assay for D2 receptor binding the compound exhibits a Ki value of greater than 300 nM.

2. (Original) A compound according to Claim 1, wherein $R_1$ is methyl.

3. (Currently amended) A compound of the formula:




or the pharmaceutically acceptable salts thereof wherein

$R_x$ is fluorine, chlorine, bromine, or iodine; and

$R_2$ and $R_3$ are the same or different and represent hydrogen, halogen, $C_1$-$C_4$ alkyl, $C_1$-$C_4$ alkoxy, alkylthio, hydroxy, amino, monoalkylamino or dialkylamino;

wherein in an assay for D2 receptor binding the compound exhibits a Ki value of greater than 300 nM.

4. (Original) A compound according to Claim 3, wherein $R_2$ and $R_3$ may not be 2-isopropoxyl and hydrogen, respectively, when $R_1$ is bromo.

5. (Original) A compound according to claim 3, wherein $R_x$ is chloride; $R_2$ and $R_3$ may not be 2-isopropoxyl and hydrogen, respectively, when $R_1$ is bromo; $R_2$ is chloride, methyl or methoxy; and $R_3$ is hydrogen or methyl.

6. (Original) A compound according to claim 5, wherein the phenyl group substituted with $R_2$ and $R_3$ is selected from the group consisting of:



7. (Currently amended) A compound of the formula:



or the pharmaceutically acceptable salts thereof wherein

$R_a$ is $C_1$-$C_4$ alkyl; and

$R_2$ and $R_3$ are the same or different and represent hydrogen, halogen, $C_1$-$C_4$ alkyl, $C_1$-$C_4$ alkoxy, alkylthio, hydroxy, amino, monoalkylamino or dialkylamino;

wherein in an assay for D2 receptor binding the compound exhibits a Ki value of greater than 300 nM.

8. (Original) A compound according to Claim 7, wherein $R_1$ is methyl.

9. (Original) A compound of according to Claim 7, wherein $R_2$ is chloride, fluoride, methyl or methoxy; and $R_3$ is hydrogen or methyl.

10. (Original) A compound according to claim 8, wherein the phenyl group substituted with $R_2$ and $R_3$ is selected from the group consisting of:




11. (Currently amended) A compound of the formula:




or the pharmaceutically acceptable salts thereof wherein:

$R_1$ is $C_1$-$C_4$ alkyl or halogen; and

wherein in an assay for D2 receptor binding the compound exhibits a Ki value of greater than 300 nM.

12. (Original) A compound according to Claim 11, wherein $R_1$ is chloro.

13-35. (Canceled)